MedPath

Magnesium and Platelet Function Testing

Completed
Conditions
Eclampsia Preeclampsia
Interventions
Other: Collect a study-specific blood sample of healthy subjects
Registration Number
NCT03143647
Lead Sponsor
Ziekenhuis Oost-Limburg
Brief Summary

Magnesium has built up the reputation of a 'natural calcium antagonist'. However, the exact effect of magnesium on coagulation and more specifically on platelet function is still disputed. An important discrepancy between in vivo and in vitro studies exists. Magnesium has thus been reported to antagonize platelets in some studies, and to stimulate platelets in other studies. Current evidence seems to point in the direction of a general antagonization of aggregation and coagulation.

Intravenous magnesium is often administered in pre-eclampsia as seizure prophylaxis. Therapeutic regimens usually consist of an intravenously administered loading dose (2-3 grams) and a maintenance infusion, targeting a plasma level of 2-3 mmol/L. Therapeutic drug monitoring is needed, as magnesium toxicity is an important concern.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
20
Inclusion Criteria
  • Signed Informed consent
  • Over 18 years of age (and younger or equal to 50 years of age) and able to provide legally binding consent
  • American Society of Anesthesiologists physical fitness scale 1 (non smoker, no or minimal alcohol use, ..)
Exclusion Criteria
  • Chronic disease
  • Chronic medical therapy (other than oral contraception)
  • Pregnancy
  • ASA 2 or higher
  • Known coagulation or aggregation disorders
  • Use of COX-inhibitors in the last 10 days
  • Contra-indications for venipuncture

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CaseCollect a study-specific blood sample of healthy subjects* Female * Pregnant with possible pre-eclampsia * Over 18 years of age * American Society of Anesthesiologists physical fitness scale 1
ControlCollect a study-specific blood sample of healthy subjects* Female * Over 18 years of age * American Society of Anesthesiologists physical fitness scale 1 * Not pregnant
Primary Outcome Measures
NameTimeMethod
PAC-t-UB test results4 months

The main endpoint of this study is the Platelet Activation Test in Unprocessed Blood (PAC-t-UB).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ziekenhuis Oost-Limburg

🇧🇪

Genk, Belgium

© Copyright 2025. All Rights Reserved by MedPath